Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 4:58 pm Sale |
2023-12-31 | 13G | Western Alliance Bancorporation WAL |
Citadel Advisors LLC | 2,705,253 2.500% |
-3,230,285 (-54.42%) |
Filing History |
| 2024-02-14 4:58 pm Sale |
2023-12-31 | 13G | Allakos Inc. ALLK |
Citadel Advisors LLC | 3,304,622 3.800% |
-1,462,307 (-30.68%) |
Filing History |
| 2024-02-14 4:58 pm Sale |
2023-12-31 | 13G | Icosavax, Inc. ICVX |
Citadel Advisors LLC | 283,079 0.600% |
-1,906,390 (-87.07%) |
Filing History |
| 2024-02-14 4:58 pm Sale |
2023-12-31 | 13G | Coherus BioSciences, Inc. CHRS |
Citadel Advisors LLC | 2,047,286 1.800% |
-3,767,788 (-64.79%) |
Filing History |
| 2024-02-14 4:58 pm Purchase |
2023-12-31 | 13G | Janux Therapeutics, Inc. JANX |
Citadel Advisors LLC | 3,125,897 6.800% |
999,762 (+47.02%) |
Filing History |
| 2024-02-14 4:58 pm Sale |
2023-12-31 | 13G | Nektar Therapeutics NKTR |
Citadel Advisors LLC | 5,635,132 3.000% |
-4,094,620 (-42.08%) |
Filing History |
| 2024-02-14 4:58 pm Purchase |
2023-12-31 | 13G | Dutch Bros Inc. BROS |
Citadel Advisors LLC | 4,073,886 6.500% |
865,013 (+26.96%) |
Filing History |
| 2024-02-14 4:58 pm Purchase |
2023-12-31 | 13G | Aclaris Therapeutics, Inc. ACRS |
Citadel Advisors LLC | 5,406,089 7.600% |
1,819,325 (+50.72%) |
Filing History |
| 2024-02-14 4:58 pm Purchase |
2023-12-31 | 13G | Expensify, Inc. EXFY |
Citadel Advisors LLC | 2,794,376 4.000% |
82,713 (+3.05%) |
Filing History |
| 2024-02-14 4:57 pm Sale |
2023-12-31 | 13G | Catcha Investment Corp CHAA |
Citadel Advisors LLC | 6,410 0.300% |
-2,198,479 (-99.71%) |
Filing History |
| 2024-02-14 4:57 pm Sale |
2023-12-31 | 13G | Project Energy Reimagined Acquisition Corp. PEGR |
Citadel Advisors LLC | 172,489 1.000% |
-2,043,562 (-92.22%) |
Filing History |
| 2024-02-14 4:57 pm Sale |
2023-12-31 | 13G | Spruce Biosciences, Inc. SPRB |
Citadel Advisors LLC | 108,240 0.300% |
-1,639,151 (-93.81%) |
Filing History |
| 2024-02-14 4:57 pm Purchase |
2023-12-31 | 13G | Ventyx Biosciences, Inc. VTYX |
Citadel Advisors LLC | 4,279,553 7.300% |
490,758 (+12.95%) |
Filing History |
| 2024-02-14 4:57 pm Sale |
2023-12-31 | 13G | Vera Therapeutics, Inc. VERA |
Citadel Advisors LLC | 43,447 0.100% |
-1,948,106 (-97.82%) |
Filing History |
| 2024-02-14 4:57 pm Sale |
2023-12-31 | 13G | Vigil Neuroscience, Inc. VIGL |
Citadel Advisors LLC | 2,161,902 6.000% |
-2,014 (-0.09%) |
Filing History |
| 2024-02-14 4:57 pm Sale |
2023-12-31 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO |
Citadel Advisors LLC | 2,084,267 7.800% |
-8,221 (-0.39%) |
Filing History |
| 2024-02-14 4:57 pm Purchase |
2023-12-31 | 13G | AN2 Therapeutics, Inc. ANTX |
Citadel Advisors LLC | 1,556,842 5.200% |
219,849 (+16.44%) |
Filing History |
| 2024-02-14 4:57 pm Sale |
2023-12-31 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL |
Citadel Advisors LLC | 3,738,482 5.300% |
-101,347 (-2.64%) |
Filing History |
| 2024-02-14 4:57 pm Sale |
2023-12-31 | 13G | VYNE Therapeutics Inc. VYNE |
Citadel Advisors LLC | 1,181,144 8.500% |
-23 (-0.00%) |
Filing History |
| 2024-02-14 4:57 pm Sale |
2023-12-31 | 13G | Korro Bio, Inc. KRRO |
Citadel Advisors LLC | 529,251 6.600% |
-16,967 (-3.11%) |
Filing History |